Targeting EB3-IP 3 R3 Interface with Cognate Peptide Protects from Acute Respiratory Distress Syndrome
Man Long Kwok,Melissa Geyer,Wan Ching Chan,Shuangping Zhao,Lianzhi Gu,Fei Huang,Steven M Vogel,Pavel A Petukhov,Yulia Komarova
DOI: https://doi.org/10.1165/rcmb.2022-0217oc
IF: 7.748
2023-06-08
American Journal of Respiratory Cell and Molecular Biology
Abstract:Acute respiratory distress syndrome (ARDS) is a lung disease characterized by acute onset of non-cardiogenic pulmonary edema, hypoxemia, and respiratory insufficiency. The current treatment for ARDS is mainly supportive in nature, providing a critical need for targeted pharmacological management. We addressed this medical problem by developing a pharmacological treatment for pulmonary vascular leakage, a culprit of alveolar damage and lung inflammation. Our novel therapeutic target is the microtubule accessory factor End Binding protein 3 (EB3), which contributes to pulmonary vascular leakage by amplifying pathological calcium signaling in endothelial cells in response to inflammatory stimuli. EB3 interacts with the inositol 1,4,5-trisphosphate receptor 3 (IP3R3) and orchestrates calcium release from endoplasmic reticulum (ER) stores. Here, we designed and tested the therapeutic benefits of the Cognate IP3 Receptor Inhibitor, a 14 amino acid peptide named CIPRI, which disrupted EB3-IP3R3 interaction in vitro and in lungs of mice challenged with endotoxin. Treatment with CIPRI or depletion of IP3R3 in lung microvascular endothelial (HLMVE) monolayers mitigated calcium release from ER stores and prevented a disassembly of Vascular endothelial cadherin (VE-cadherin) junctions in response to the pro-inflammatory mediator α-thrombin. Furthermore, intravenous administration of CIPRI in mice mitigated inflammation-induced lung injury, blocked pulmonary microvascular leakage, prevented activation of NFAT signaling, and reduced production of pro-inflammatory cytokines in the lung tissue. CIPRI also improved survival of mice from both endotoxemia and polymicrobial sepsis. Together, these data demonstrate that targeting EB3-IP3R3 interaction with a cognate peptide is a promising strategy to address hyperpermeability of microvessels in inflammatory lung diseases.
biochemistry & molecular biology,cell biology,respiratory system